Gene therapy for Parkinson's disease

Expert Reviews in Molecular Medicine

Volumn 6, Issue 5, 2004, Pages

  Lawlor, Patricia A ^a   During, Matthew J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adeno associated virus; Apoptosis; GAD; GDNF; Gene therapy; Glial cell line derived neurotrophic factor; Glutamic acid decarboxylase; Neuroprotection; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GROWTH FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; NEUROTRANSMITTER; OXIDOPAMINE; TETRAHYDROBIOPTERIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; VIRUS VECTOR; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

ANOREXIA; BASAL GANGLION; CELL SURVIVAL; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISORIENTATION; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG SAFETY; DYSKINESIA; ENZYME ACTIVITY; GENE THERAPY; HALLUCINATION; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; NERVE REGENERATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STRIATE CORTEX; SUBSTANTIA NIGRA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ADENO-ASSOCIATED VIRUS;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; DOPAMINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LEVODOPA; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 23844448882     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S146239940400746X     Document Type: Review

References (149)

1. Zigmond, M.J., Hastings, T.G. and Perez, R.G. (2002) Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 8, 389-393,
2. Lewis, S.J.G., Caldwell, M.A. and Barker, R.A. (2003) Modern therapeutic approaches in Parkinson's disease. Expert Rev. Mol. Med. 5, 28 March, DOI: 10.1017/S1462399403006008
3. Cotzias, G.C., Van Woert, M.H. and Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276, 374-379,
4. Kordower, J.H. and Goetz, C.G. (1999) The first miracle in neurodegenerative disease: the discovery of oral levodopa. Brain Res Bull 50, 377-378,
5. Marsden, C.D. and Parkes, J.D. (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1, 345-349,
6. Dunnett, S.B. and Bjorklund, A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32-39,
7. Fearnley, J.M. and Lees, A.J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5), 2283-2301,
8. Hornykiewicz, O. (2001) Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease. J Chem Neuroanat 22, 3-12,
9. Rajput, A.H. et al. (1987) Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 14, 414-418,
10. Smargiassi, A. et al. (1998) A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 19, 709-712,
11. Butterfield, P.G. et al. (1993) Environmental antecedents of young-onset Parkinson's disease. Neurology 43, 1150-1158,
12. Sherer, T.B., Betarbet, R. and Greenamyre, J.T. (2002) Environment, mitochondria, and Parkinson's disease. Neuroscientist 8, 192-197,
13. Hubble, J.P. et al. (1993) Risk factors for Parkinson's disease. Neurology 43, 1693-1697,
14. Chaturvedi, S. et al. (1995) Environmental exposures in elderly Canadians with Parkinson's disease. Can J Neurol Sci 22, 232-234,
15. Polymeropoulos, M.H. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047,
16. Kruger, R. et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18, 106-108,
17. Kitada, T. et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608,
18. Leroy, E. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452,
19. Leroy, E., Boyer, R. and Polymeropoulos, M.H. (1998) Intron-exon structure of ubiquitin c-terminal hydrolase-L1. DNA Res 5, 397-400,
20. Anglade, P. et al. (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12, 603-610,
21. Mochizuki, H. et al. (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137, 120-123,
22. Anglade, P. et al. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12, 25-31,
23. Tompkins, M.M. et al. (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 150, 119-131,
24. Hirsch, E.C. et al. (1999) Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 14, 383-385,
25. Kosel, S. et al. (1997) On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl) 93, 105-108,
26. Banati, R.B., Daniel, S.E. and Blunt, S.B. (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13, 221-227,
27. Hartmann, A. et al. (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97, 2875-2880,
28. Tatton, N.A. (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166, 29-43,
29. Andersen, J.K. (2001) Does neuronal loss in Parkinson's disease involve programmed cell death? Bioessays 23, 640-646,
30. Tatton, W.G. et al. (2003) Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53 Suppl 3, S61-70; discussion S70-62,
31. Fahn, S. (1996) Is levodopa toxic? Neurology 47, S184-195,
32. Obeso, J.A. et al. (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 6, 889-897,
33. Chase, T.N., Mouradian, M.M. and Engber, T.M. (1993) Motor response complications and the function of striatal efferent systems. Neurology 43, S23-27,
34. Mandel, R.J. et al. (1999) Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol 159, 47-64,
35. Hsich, G., Sena-Esteves, M. and Breakefield, X.O. (2002) Critical issues in gene therapy for neurologic disease. Hum Gene Ther 13, 579-604,
36. Burton, E.A., Glorioso, J.C. and Fink, D.J. (2003) Gene therapy progress and prospects: Parkinson's disease. Gene Ther 10, 1721-1727,
37. Kaplitt, M.G. et al. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8, 148-154,
38. Klein, R.L. et al. (1998) Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 150, 183-194,
39. Davidson, B.L. et al. (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97, 3428-3432,
40. Akli, S. et al. (1993) Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 3, 224-228,
41. Davidson, B.L. et al. (1993) A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 3, 219-223,
42. Horellou, P. et al. (1994) Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 6, 49-53,
43. Bohn, M.C. et al. (1999) Adenovirus-mediated transgene expression in nonhuman primate brain. Hum Gene Ther 10, 1175-1184,
44. Naldini, L. et al. (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93, 11382-11388,
45. Blomer, U. et al. (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71, 6641-6649,
46. Kordower, J.H. et al. (1999) Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160, 1-16,
47. Bjorklund, A. et al. (2000) Towards a neuroprotective gene theraphy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886, 82-98,
48. Clark, K.R. et al. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 10, 1031-1039,
49. Cao, L. et al. (2000) High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 74, 11456-11463,
50. Mastakov, M.Y. et al. (2001) Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol Ther 3, 225-232,
51. Bankiewicz, K.S. et al. (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164, 2-14,
52. Lloyd, K.G. (1977) CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Biol 90, 255-266,
53. Zigmond, M.J. (1997) Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4, 247-253,
54. Bezard, E. et al. (2001) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb J 15, 1092-1094,
55. Bezard, E. et al. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21, 6853-6861,
56. Moore, R.Y. (2003) Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease. Parkinsonism Relat Disord 9 Suppl 2, S65-71,
57. Langston, J.W. et al. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980,
58. Langston, J.W. et al. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46, 598-605,
59. Betarbet, R. et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3, 1301-1306,
60. Ungerstedt, U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5, 107-110,
61. Sauer, H. and Oertel, W.H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415,
62. Dauer, W. and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909,
63. Ungerstedt, U. and Arbuthnott, G.W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24, 485-493,
64. Olsson, M. et al. (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15, 3863-3875,
65. Borlongan, C.V. and Sanberg, P.R. (1995) Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 15, 5372-5378,
66. Barneoud, P. et al. (1995) Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 67, 837-848,
67. Chang, J.W. et al. (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88, 617-628,
68. Henderson, J.M. et al. (1999) Subthalamic nucleus lesions induce deficits as well as benefits in the hemiparkinsonian rat. Eur J Neurosci 11, 2749-2757,
69. Barneoud, P. et al. (2000) Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system. Eur J Neurosci 12, 322-336,
70. Kirik, D. et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22, 2780-2791,
71. Kirik, D. et al. (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 100, 2884-2889,
72. Chase, T.N. et al. (1989) Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39, 7-10; discussion 19,
73. Schuh, L.A. and Bennett, J.P., Jr. (1993) Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 43, 1545-1550,
74. Nagatsu, T., Levitt, M. and Udenfriend, S. (1964) Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues. Biochem Biophys Res Commun 14, 543-549,
75. Nagatsu, T. et al. (1984) Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases. Adv Neurol 40, 467-473,
76. Nagatsu, T. and Ichinose, H. (1999) Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease. Cell Mol Neurobiol 19, 57-66,
77. Horellou, P. et al. (1990) In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 5, 393-402,
78. Horellou, P. et al. (1990) Behavioural Effect of Engineered Cells that Synthesize l-dopa or Dopamine after Grafting into the Rat Neostriatum. Eur J Neurosci 2, 116-119,
79. Fisher, L.J. et al. (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371-380,
80. During, M.J. et al. (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403,
81. Bencsics, C. et al. (1996) Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J Neurosci 16, 4449-4456,
82. Leff, S.E. et al. (1998) In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosine hydroxylase. Exp Neurol 151, 249-264,
83. Mandel, R.J. et al. (1998) Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 18, 4271-4284,
84. Corti, O. et al. (1999) Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci U S A 96, 12120-12125,
85. Sanchez-Pernaute, R. et al. (2001) Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther 4, 324-330,
86. Leff, S.E. et al. (1999) Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 92, 185-196,
87. Fan, D.S. et al. (1998) Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 9, 2527-2535,
88. During, M.J. et al. (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 5, 820-827,
89. Shen, Y. et al. (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 11, 1509-1519,
90. Muramatsu, S. et al. (2002) Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13, 345-354,
91. Azzouz, M. et al. (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22, 10302-10312,
92. Kirik, D. et al. (2002) Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 99, 4708-4713,
93. Lee, W.Y. et al. (1999) Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. J Neurosci 19, 3266-3274,
94. Ferrari, G. et al. (1989) Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev Biol 133, 140-147,
95. Knusel, B. et al. (1990) Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci 10, 558-570,
96. Park, T.H. and Mytilineou, C. (1992) Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF. Brain Res 599, 83-97,
97. Hyman, C. et al. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230-232,
98. Miao, N. et al. (1997) Sonic hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult In vitro. J Neurosci 17, 5891-5899,
99. Ventrella, L.L. (1993) Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigrostriatal pathway. J Neurosurg Sci 37, 1-8,
100. Zeng, B.Y., Jenner, P. and Marsden, C.D. (1996) Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation. Exp Neurol 139, 214-226,
101. Pearce, R.K. et al. (1996) Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset. Synapse 23, 192-200,
102. Svendsen, C.N. et al. (1996) Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol 137, 376-388,
103. Klein, R.L. et al. (1999) Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res 847, 314-320,
104. Pearce, R.K. et al. (1999) Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J Neural Transm 106, 663-683,
105. Tsuboi, K. and Shults, C.W. (2002) Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease. Exp Neurol 173, 95-104,
106. Dass, B. et al. (2002) Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Neuroscience 114, 99-109,
107. Lin, L.F. et al. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132,
108. Sauer, H., Rosenblad, C. and Bjorklund, A. (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci U S A 92, 8935-8939,
109. Bowenkamp, K.E. et al. (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 355, 479-489,
110. Rosenblad, C. et al. (1999) Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11, 1554-1566,
111. Kirik, D., Rosenblad, C. and Bjorklund, A. (2000) Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12, 3871-3882,
112. Winkler, C. et al. (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16, 7206-7215,
113. Rosenblad, C., Martinez-Serrano, A. and Bjorklund, A. (1998) Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82, 129-137,
114. Kirik, D. et al. (2001) Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 13, 1589-1599,
115. Gash, D.M. et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255,
116. Zhang, Z. et al. (1997) Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 282, 1396-1401,
117. Kordower, J.H. et al. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46, 419-424,
118. Nutt, J.G. et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73,
119. Grondin, R. et al. (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191-2201,
120. Gill, S.S. et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9, 589-595,
121. Lapchak, P.A. et al. (1997) Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 747, 92-102,
122. Choi-Lundberg, D.L. et al. (1997) Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841,
123. Choi-Lundberg, D.L. et al. (1998) Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154, 261-275,
124. Bilang-Bleuel, A. et al. (1997) Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 94, 8818-8823,
125. Connor, B. et al. (1999) Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther 6, 1936-1951,
126. Connor, B. et al. (2001) Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp Neurol 169, 83-95,
127. Lapchak, P.A. et al. (1997) Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 777, 153-160,
128. Kozlowski, D.A. et al. (2000) Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 166, 1-15,
129. Mandel, R.J. et al. (1997) Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 94, 14083-14088,
130. Kirik, D. et al. (2000) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20, 4686-4700,
131. Georgievska, B. et al. (2002) Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13, 75-82,
132. Wang, L. et al. (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9, 381-389,
133. Kordower, J.H. et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773,
134. Palfi, S. et al. (2002) Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22, 4942-4954,
135. Georgievska, B., Kirik, D. and Bjorklund, A. (2002) Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177, 461-474,
136. Baumgartner, B.J. and Shine, H.D. (1997) Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J Neurosci 17, 6504-6511,
137. Limousin, P. et al. (1995) Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 10, 672-674,
138. Limousin, P. et al. (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345, 91-95,
139. Gill, S.S. and Heywood, P. (1997) Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 350, 1224,
140. Alvarez, L. et al. (2001) Dorsal subthalamotomy for Parkinson's disease. Mov Disord 16, 72-78,
141. Patel, N.K. et al. (2003) Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain 126, 1136-1145,
142. Levy, R. et al. (2001) Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. Brain 124, 2105-2118,
143. Luo, J. et al. (2002) Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298, 425-429,
144. During, M.J. et al. (2001) Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12, 1589-1591,
145. Gossen, M. et al. (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769,
146. Fitzsimons, H.L., McKenzie, J.M. and During, M.J. (2001) Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain. Gene Ther 8, 1675-1681,
147. Fitzsimons, H.L., Bland, R.J. and During, M.J. (2002) Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 28, 227-236,
148. Vigna, E. et al. (2002) Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 5, 252-261,
149. Vigna, E. et al. (2003) The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18, 738-750,